ZA986636B - A pharmaceutical composition active in reducing production of MCP-1 protein - Google Patents

A pharmaceutical composition active in reducing production of MCP-1 protein

Info

Publication number
ZA986636B
ZA986636B ZA986636A ZA986636A ZA986636B ZA 986636 B ZA986636 B ZA 986636B ZA 986636 A ZA986636 A ZA 986636A ZA 986636 A ZA986636 A ZA 986636A ZA 986636 B ZA986636 B ZA 986636B
Authority
ZA
South Africa
Prior art keywords
mcp
protein
pharmaceutical composition
reducing production
composition active
Prior art date
Application number
ZA986636A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Alberto Mantovani
Original Assignee
Angelini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini Ricerche Spa filed Critical Angelini Ricerche Spa
Publication of ZA986636B publication Critical patent/ZA986636B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA986636A 1997-07-28 1998-07-24 A pharmaceutical composition active in reducing production of MCP-1 protein ZA986636B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI001789A IT1293795B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1

Publications (1)

Publication Number Publication Date
ZA986636B true ZA986636B (en) 1999-02-04

Family

ID=11377642

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986636A ZA986636B (en) 1997-07-28 1998-07-24 A pharmaceutical composition active in reducing production of MCP-1 protein

Country Status (16)

Country Link
US (1) US6534534B1 (de)
EP (1) EP1005332B1 (de)
JP (2) JP4651191B2 (de)
AR (1) AR016382A1 (de)
AT (1) ATE251902T1 (de)
AU (1) AU744492B2 (de)
CA (1) CA2300289C (de)
DE (1) DE69819012T2 (de)
DK (1) DK1005332T3 (de)
ES (1) ES2207858T3 (de)
HK (1) HK1028561A1 (de)
IT (1) IT1293795B1 (de)
PT (1) PT1005332E (de)
SI (1) SI1005332T1 (de)
WO (1) WO1999004770A2 (de)
ZA (1) ZA986636B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
HUE026910T2 (en) * 2008-03-07 2016-07-28 Acraf 1-Benzyl-3-hydroxymethylindazole derivatives and their use in the treatment of MCP-1 and CX3CR1 expression-based diseases
PL2254869T3 (pl) * 2008-03-07 2017-10-31 Acraf Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40
PL2262778T3 (pl) * 2008-03-07 2020-02-28 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CXCR1 i p40
KR101736301B1 (ko) 2009-08-03 2017-05-29 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 1-벤질-3-하이드록시메틸-1ｈ-인다졸 및 이의 유도체 및 필요한 마그네슘 중간체들의 제조 방법
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP2539710A4 (de) 2010-02-25 2016-07-06 Prairie Ventures Llc System und verfahren zur handhabung, lagerung und analyse anatomischer krankheitserregerproben
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
JP6944442B2 (ja) 2015-06-12 2021-10-06 ベットーレ リミテッド ライアビリティー カンパニーＶｅｔｔｏｒｅ， Ｌｌｃ 疾患を治療するためのｍｃｔ４阻害剤
WO2018111904A1 (en) 2016-12-12 2018-06-21 Vettore, LLC Heterocyclic inhibitors of mct4
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
AU5537994A (en) 1992-10-22 1994-05-09 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JPH08333262A (ja) * 1995-04-07 1996-12-17 Chugai Pharmaceut Co Ltd 免疫抑制剤
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1

Also Published As

Publication number Publication date
SI1005332T1 (en) 2004-02-29
DE69819012D1 (de) 2003-11-20
DK1005332T3 (da) 2004-02-09
JP2001510793A (ja) 2001-08-07
IT1293795B1 (it) 1999-03-10
ES2207858T3 (es) 2004-06-01
WO1999004770A3 (en) 1999-04-15
ATE251902T1 (de) 2003-11-15
CA2300289C (en) 2007-11-20
PT1005332E (pt) 2004-03-31
JP2010047609A (ja) 2010-03-04
AR016382A1 (es) 2001-07-04
US6534534B1 (en) 2003-03-18
JP5086322B2 (ja) 2012-11-28
HK1028561A1 (en) 2001-02-23
DE69819012T2 (de) 2004-08-12
EP1005332A2 (de) 2000-06-07
ITMI971789A1 (it) 1999-01-28
WO1999004770A2 (en) 1999-02-04
CA2300289A1 (en) 1999-02-04
AU744492B2 (en) 2002-02-28
AU9160198A (en) 1999-02-16
JP4651191B2 (ja) 2011-03-16
EP1005332B1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
HUP0103616A3 (en) Therapeutically active proteins in plants
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
IL123986A0 (en) Antithombotic agents process for their preparation and pharmaceutical compositions comprising them
ZA982533B (en) Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
HUP9601698A3 (en) Pharmaceutical composition of adiabetical activity
ZA989740B (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
HU9502918D0 (en) Pharmaceutical composition of antihypertriglyceridemic activity
ZA986636B (en) A pharmaceutical composition active in reducing production of MCP-1 protein
ZA984266B (en) Pharmaceutical composition and process of preparation
IL138137A (en) Cholenic acid amides and pharmaceutical compositions thereof
HUP0003189A2 (en) Pharmaceutical composition comprising fexofenadine and its derivatives
ZA983239B (en) Stable active human ob protein compositions and methods
HUP9802716A3 (en) Pharmaceutical composition of analgesic activity
IL134050A0 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
PL337807A1 (en) Sertralin dosage formulation in the form of a gelatine-encapsulated solution
AU5337198A (en) Production of biologically active polypeptides
ZA9811105B (en) Cosmetic and pharmaceutical composition
ZA9810846B (en) An active hedgehog-protein-mutant a process for its preparation and its use for pharmaceutical purposes
HU9702369D0 (en) Pharmaceutical composition of natural active components
GB9711697D0 (en) Biologically and therapeutically active agents
GB9915380D0 (en) Biologically and therapeutically active agents
GB9814238D0 (en) Biologically and therapeutically active agents
GB9720963D0 (en) Pharmaceutical compositions and method of production
GB9409478D0 (en) Biologically and therapeutically active agents
GB9408684D0 (en) Biologically and therapeutically active agents